MX2022000928A - Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona. - Google Patents

Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona.

Info

Publication number
MX2022000928A
MX2022000928A MX2022000928A MX2022000928A MX2022000928A MX 2022000928 A MX2022000928 A MX 2022000928A MX 2022000928 A MX2022000928 A MX 2022000928A MX 2022000928 A MX2022000928 A MX 2022000928A MX 2022000928 A MX2022000928 A MX 2022000928A
Authority
MX
Mexico
Prior art keywords
fluticasone propionate
preparation
ophthalmic aqueous
nanosuspensions
nanocrystals
Prior art date
Application number
MX2022000928A
Other languages
English (en)
Inventor
Tomas Navratil
Jean- Michel BUKOWSKI
Akshay Nadkarni
José L Boyer
Brigitte Duquesroix-Chakroun
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Publication of MX2022000928A publication Critical patent/MX2022000928A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a un proceso mejorado de fabricación de nanosuspensiones acuosas oftálmicas tópicas estériles de nanocristales de la Forma A de propionato de fluticasona; las nanosuspensiones oftálmicas tópicas estériles son útiles en el tratamiento de afecciones de inflamación ocular tales como blefaritis, blefaritis posterior, disfunción de la glándula de Meibomio y ojo seco mediante la administración tópica de dichas nanosuspensiones a los párpados, pestañas y margen de los párpados.
MX2022000928A 2019-07-23 2020-07-21 Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona. MX2022000928A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US201962942551P 2019-12-02 2019-12-02
PCT/IB2020/056832 WO2021014348A1 (en) 2019-07-23 2020-07-21 Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

Publications (1)

Publication Number Publication Date
MX2022000928A true MX2022000928A (es) 2022-02-22

Family

ID=71738074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000928A MX2022000928A (es) 2019-07-23 2020-07-21 Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona.

Country Status (21)

Country Link
US (3) US11406596B2 (es)
EP (1) EP3769753B1 (es)
JP (2) JP7021301B2 (es)
KR (1) KR20220038443A (es)
CN (2) CN111821261B (es)
AU (1) AU2020317084A1 (es)
CA (1) CA3145055A1 (es)
CY (1) CY1124930T1 (es)
DK (1) DK3769753T3 (es)
ES (1) ES2905793T3 (es)
HR (1) HRP20220165T1 (es)
HU (1) HUE057416T2 (es)
LT (1) LT3769753T (es)
MD (1) MD3769753T2 (es)
MX (1) MX2022000928A (es)
PL (1) PL3769753T3 (es)
PT (1) PT3769753T (es)
RS (1) RS62932B1 (es)
SI (1) SI3769753T1 (es)
TW (1) TW202116326A (es)
WO (1) WO2021014348A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639070B2 (en) * 1992-05-06 2010-09-08 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
JP2012528889A (ja) 2009-06-05 2012-11-15 アーシエックス セラピューティックス， インコーポレイテッド フルチカゾンの眼科処方物および使用方法
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
US20130065888A1 (en) * 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
RU2663117C2 (ru) 2012-05-08 2018-08-01 Никокс Офтэлмикс, Инк. Препараты гидрофобных терапевтических средств, способы их получения и применения
BR112015014262A8 (pt) * 2012-12-17 2019-10-08 Glaxo Group Ltd formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑

Also Published As

Publication number Publication date
PT3769753T (pt) 2022-02-15
CN115120557A (zh) 2022-09-30
MD3769753T2 (ro) 2022-04-30
US20210023001A1 (en) 2021-01-28
HUE057416T2 (hu) 2022-05-28
LT3769753T (lt) 2022-05-10
AU2020317084A1 (en) 2022-03-03
KR20220038443A (ko) 2022-03-28
CN111821261B (zh) 2022-07-26
CA3145055A1 (en) 2021-01-28
JP7494230B2 (ja) 2024-06-03
RS62932B1 (sr) 2022-03-31
EP3769753A1 (en) 2021-01-27
CN115120557B (zh) 2024-05-07
CY1124930T1 (el) 2023-01-05
JP2021017449A (ja) 2021-02-15
JP2022062172A (ja) 2022-04-19
US11406596B2 (en) 2022-08-09
PL3769753T3 (pl) 2022-04-04
WO2021014348A1 (en) 2021-01-28
JP7021301B2 (ja) 2022-02-16
SI3769753T1 (sl) 2022-04-29
DK3769753T3 (da) 2022-01-31
US20220323352A1 (en) 2022-10-13
ES2905793T3 (es) 2022-04-12
EP3769753B1 (en) 2021-11-17
HRP20220165T1 (hr) 2022-04-29
TW202116326A (zh) 2021-05-01
US20220241296A1 (en) 2022-08-04
CN111821261A (zh) 2020-10-27

Similar Documents

Publication Publication Date Title
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
MX2019001877A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX2022000928A (es) Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona.
WO2015138628A8 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
EP4279063A3 (en) Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2023009352A (es) Metodos para la administracion oftalmica de roflumilast.
MX2020009132A (es) Composiciones farmaceuticas que comprenden nebivolol.
RU2017111579A (ru) Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2020012012A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
AU2017261303A1 (en) Ophthalmic compositions
BR112022001202A2 (pt) Processo para a preparação de propionato aquoso de fluticasona estéril na form a suspensões de nanocristas
BR112019000059A2 (pt) tratamento de doença vascular da retina com o uso de células progenitoras
WO2019090010A3 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
AU2020299145A8 (en) Compositions and methods for treating eye diseases
MA53146B1 (fr) Procédé de préparation de suspensions aqueuses ophtalmiques stériles de nanocristaux de forme a de propionate de fluticasone
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки